Targeting leukemic stem cells
Acute myeloid leukemia (AML) remains a devastating disease with less than 30 % of patients surviving five years after diagnosis. The resistance of AML is driven by small subpopulations of leukemic stem cells (LSCs), which survive chemotherapy and elude immune surveillance. LSCs have growth advantages induced by oncogenic mutations but are in many ways similar to healthy hematopoietic stem cells (HSCs). LSCs are located in protective bone marrow niches promoting stemness and therapy resistance and modify these to displace HSCs for their own expansion. The EU-funded Hemstem project explores strategies to target LSCs based on the knowledge of the complex interactions between LSCs and HSCs and provides a rationale for novel treatments.
Call for proposal
See other projects for this call